(株)免疫生物研究所の貸借残高情報
| 主市場 | 業種 | 証券コード/EDINET | 英名称 |
|---|---|---|---|
| 東証GRT | 医薬品 | 4570/E00986 | Immuno-Biological Laboratories Co.,Ltd. |
| 公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
|---|---|---|---|---|---|---|---|---|---|
| 2013/12/27 | 日証協 | 235,000株 | +0.34% | 4,170株 | +421.25% | 181,523株 | -4.62% | 8,410株 | +31% |
| 2013/12/20 | 日証協 | 234,200株 | -1.43% | 800株 | 0% | 190,313株 | +1.83% | 6,420株 | +668.86% |
| 2013/12/13 | 日証協 | 237,600株 | 0% | 800株 | 0% | 186,893株 | -0.09% | 835株 | -89.43% |
| 2013/12/06 | 日証協 | 237,600株 | 0% | 0株 | -100% | 187,068株 | +2.37% | 7,900株 | +364.71% |
| 2013/11/29 | 日証協 | 237,600株 | -10.81% | 5,800株 | 0% | 182,733株 | -7.16% | 1,700株 | +108.33% |
| 2013/11/22 | 日証協 | 266,400株 | -0.15% | 0株 | -100% | 196,833株 | +0.11% | 816株 | -88.67% |
| 2013/11/15 | 日証協 | 266,800株 | +2.5% | 6,200株 | +93.75% | 196,617株 | +4.13% | 7,200株 | +38.46% |
| 2013/11/08 | 日証協 | 260,300株 | +0.42% | 3,200株 | +433.33% | 188,817株 | +1.23% | 5,200株 | -18.8% |
| 2013/11/01 | 日証協 | 259,200株 | -0.23% | 600株 | 0% | 186,517株 | +0.7% | 6,404株 | +25.57% |
| 2013/10/25 | 日証協 | 259,800株 | -1.37% | 600株 | 0% | 185,213株 | -1.33% | 5,100株 | +130.98% |
| 2013/10/18 | 日証協 | 263,400株 | -8.32% | 0株 | -100% | 187,713株 | -3.29% | 2,208株 | -91.51% |
| 2013/10/11 | 日証協 | 287,300株 | +21.85% | 42,100株 | -69.46% | 194,105株 | +16.94% | 26,000株 | -62.89% |
| 2013/10/04 | 日証協 | 235,790株 | +960.68% | 137,850株 | +58.1% | 165,990株 | +189.28% | 70,057株 | +10.38% |
| 2013/09/27 | 日証協 | 22,230株 | -0.09% | 87,190株 | 0% | 57,380株 | +216.54% | 63,471株 | +9999.99% |
| 2013/09/20 | 日証協 | 22,250株 | +0.09% | 0株 | -100% | 18,127株 | +2.31% | 230株 | -70.21% |
| 2013/09/13 | 日証協 | 22,230株 | -4.22% | 260株 | +271.43% | 17,717株 | -0.43% | 772株 | +26.14% |
| 2013/09/06 | 日証協 | 23,210株 | -0.34% | 70株 | -36.36% | 17,794株 | 0% | 612株 | +143.82% |
| 2013/08/30 | 日証協 | 23,290株 | -0.17% | 110株 | -97.44% | 17,794株 | +0.19% | 251株 | -84.92% |
| 2013/08/23 | 日証協 | 23,330株 | +2.64% | 4,300株 | +372.53% | 17,761株 | +1.91% | 1,665株 | +927.78% |
※株式分割は考慮していませんのでご注意ください。